Retinoid therapy for acne: A comparative review

American Journal of Clinical Dermatology

Volumn 6, Issue 1, 2005, Pages 13-19

  Chivot, Martine ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; RETINOIC ACID; RETINOID; RETINOL DERIVATIVE; SILVER NITRATE; TAZAROTENE;

ACNE; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BONE DISEASE; CLINICAL TRIAL; COMEDO; DETERIORATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEVER; GROWTH DISORDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MUCOCUTANEOUS DISEASE; MYALGIA; PRIORITY JOURNAL; PYOGENIC GRANULOMA; REMISSION; REVIEW; SKIN DISEASE; SUPERINFECTION; TERATOGENICITY;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; BONE DISEASES; GROWTH DISORDERS; HUMANS; RECURRENCE; RETINOIDS;

EID: 14244264995     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200506010-00002     Document Type: Review

References (29)

1. Elder JT, Fischer GJ, Zhang O, et al. Retinoic acid gene receptor expression in human skin. J Invest Dermatol 1991; 96: 425-33
2. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998; 139 Suppl. 52: 34-40
3. Nyirady J, Nihland M, Payonk G, et al. A comparative evaluation of tretinoin gel microsphere, versus tretinoin cream 0,025% in reducing facial shine. Cutis 2000 Aug; 66 (2); 153-6
4. Leyden JL. Emerging topical retinoid therapies. J Am Acad Dermatol 1998; 38: S1-4
5. Cunliffe W, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomised trials. Br J Dermatol 1998; 139: 48-56
6. Thiboutot D, Gold M, Jarrat M, et al. Randomized controlled trial of the tolerability, safety and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001; 68: 10-9
7. Cunliffe W, Damby W, Dunlap F, et al. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.01% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12: 350-4
8. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis 2001; 68: 48-54
9. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol 2003; 4 (3): 197-202
10. Dominguez J, Hojyo MT, Celayo JL, et al. Topical isotretinoin vs topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998 Jan; 37 (1): 54-5
11. Michel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br J Dermatol 1998; 139: 3-7
12. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris; a multicenter trial. J Am Acad Dermatol 1996; 34: 482-5
13. Wolff JE. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther 2002; 19: 109-18
14. Bershad S, Kranjac Singer G, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized-vehicle control trial of short contact therapy with 0.1 tazarotene gel. Arch Dermatol 2002 Apr; 138 (4): 481-9
15. Bershad S, Poulin YP, Berson DS, et al. Topical retinoids in the treatment of acne vulgaris. Cutis 1999 Aug; 64 (2 Suppl.): 8-20
16. Bershad S. Development in topical retinoid therapy for acne. Semin Cutan Med Surg 2001 Sep; 20 (3): 154-61
17. Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979 Feb 15; 300 (7): 329-33
18. Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol 2001; 45: S129-35
19. Strauss JS, Leyden JJ, Lucky AW, et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001; 45: 187-95
20. Geiger JM, Hommel L, Harms M, et al. Oral 13-cis-retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. J Am Acad Dermatol 1996; 36: 513-5
21. Cunliffe WJ, Morris JFB. Isotretinoin: an explanation for its long term benefit. Dermatologica 1987; 175 Suppl. 1: 133-7
22. Strauss JS, Leyden JJ, Lucky AW, et al. Safety of a new mjcronized formulation of isotretinoin in patients with severe nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001; 45: 196-207
23. Chivot M. Residual acne lesions after treatment. Ann Dermatol Venereol 1996; 123 (9): 594-600
24. Wisowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002; 46 (4): 505-9
25. Milstone ML, Guire MC, Ablow RC. Premature epiphysal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 1982; 7: 663-6
26. Marini JC, Hill S, Zasloff MA. Dense metaphysal bands and growth arrest associated with isotretinoin therapy. Am J Dis Child 1988; 142 (3): 316-8
27. Nishimura G, Mugishima H, Hirao J, et al. Generalised metaphysal modification with cone-shaped epiphyses following long-term administration of 13-cis retinoic acid. Eur J Pediatr 1997; 156: 432-5
28. Chivot M. Acne flare-up and deterioration with oral isotretinoin. Ann Dermatol Venereol 2001; 128: 224-8
29. Macdonald-Hull S, Cunliffe WJ. The safety of isotretinoin in patients with systemic diseases. J Dermatol Treat 1989; 1: 35-7